More than one billion people around the world live with obesity. A new class of drugs has arrived that can genuinely help. And yet, according to the World Health Organization, fewer than 10% of those who could benefit will have access to these medications by 2030. (Source: Drivingeco)
That gap tells you almost everything you need to know about where we are right now.
What Are GLP-1 Drugs and Why Is Everyone Talking About Them?
Wegovy and Ozempic are both brand names for the same active ingredient: semaglutide. It belongs to a class of medications called GLP-1 receptor agonists, which were originally developed to treat type 2 diabetes. Ozempic received FDA approval for diabetes in 2017. Wegovy followed in 2021, approved specifically for obesity and weight management.
The results have been hard to ignore. Clinical trials showed significant weight loss in patients and that was just the beginning. More recent research from Harvard Medical School and the Technical University of Munich found that these drugs also protect the heart. They reduce the risk of cardiovascular events, lower blood pressure, and improve kidney function.
In December 2025, the WHO made a landmark move and conditionally recommended GLP-1 medications as a long-term treatment for obesity, which is its most significant stance on obesity treatment in decades. The science, in short, is compelling. (Source: Drivingeco)
So why aren’t more people getting these drugs?
The Price Wall: A Treatment Most People Can’t Afford
Here is where the story gets complicated. In the United States, Wegovy costs between $800 and $1,300 per month without insurance. Eli Lilly’s competitor drug Zepbound offers some discounted options for uninsured patients, but affordability remains out of reach for most.
A 2024 study found that 69% of U.S. adults lacked insurance coverage for GLP-1 medications at all. (Source: Equilibrium) Prescriptions for semaglutide did surge by more than 400% between January 2021 and December 2023, according to research published in JAMA Health Forum. (Source: USC Today) But that growth was driven almost entirely by people with private insurance.
For those on Medicare or Medicaid (the public programs that cover older and lower-income Americans) the picture looks very different.
Medicare Part D accounted for barely 1.2% of Wegovy prescription fills in 2023. The reason? Medicare only covers the drug for obesity if a patient already has a qualifying comorbidity like cardiovascular disease. As one USC researcher put it plainly: “You have to be sick enough, then we’ll cover that medication for you.” (Source: USC Today)
That is the catch-22 at the heart of this crisis.
Who Is Actually Being Left Out?
The equity problem here runs deep. Obesity rates in the U.S. are disproportionately higher among economically disadvantaged populations, which are exactly the people with the least insurance coverage and the fewest options.
Researchers estimate that expanding access to these drugs for Medicaid beneficiaries alone could prevent 8,970 deaths per year. And among elderly Medicare patients, expanded access could avert an additional 7,480 annual deaths.
These are not hypothetical numbers. They represent real people who are currently not getting a treatment that exists.
There is also a troubling dynamic happening at the other end of the spectrum. Wealthy, non-obese individuals are using these drugs off-label for cosmetic weight loss, often driven by celebrity endorsements and social media trends. This creates shortages and pushes those with a genuine medical need further back in the queue.
Making the situation worse: most patients who do start the drugs don’t stay on them. An April 2025 study found that only 14.3% of patients remained on therapy after two years. The number one reason? Cost. (Source: ICER)
How Different Healthcare Systems Are Responding
The access gap isn’t just an American problem, it’s global!
In the UK, the NHS approved Wegovy via NICE in 2023, but access has been deliberately staged. As of 2026, patients need a BMI of 35 or above with at least one weight-related condition, plus a referral to a specialist Tier 3 weight management service, which itself comes with long waiting times. (Source: The Carepharmacy) In April 2026, NICE expanded its guidance to include patients with cardiovascular disease, potentially opening access to 1.2 million more people in England. (Source:CNBC) A step forward, though critics warn it risks creating a two-tier system where only the most severely ill qualify on the NHS, while everyone else pays privately.
In low- and middle-income countries, the situation is starker. The WHO itself acknowledges that the $800–$1,300 monthly price tag makes systemic adoption. (Source: Drivingeco)
Meanwhile, in the U.S., insurance payers have been rejecting between 70% and 80% of GLP-1 claims, according to IQVIA market data. (Source: IQVIA) There is no national rollout plan, even as the scale of the crisis grows.
What This Means for Healthcare Systems Long-Term
Here is the uncomfortable math. The U.S. currently spends an estimated $173 billion every year treating obesity-related diseases like diabetes, heart disease, and sleep apnea. That is more than the annual budgets of 42 U.S. states combined.
The economic case for covering these drugs broadly is strong. Treating the condition early, before it leads to heart attacks, strokes, and chronic illness, is almost certainly cheaper than treating the consequences. But insurance companies and governments are focused on short-term drug costs, not long-term savings.
As STAT News noted in August 2025, the rollout of GLP-1 drugs has been “one of the rockiest rollouts of a major medical advance in the United States.” (Source: STAT News) Despite the clinical evidence, despite the death toll, there is still no coordinated plan.
A Revolution With an Asterisk
GLP-1 drugs like Wegovy represent a genuine turning point in how medicine treats obesity. The science is solid. The benefits are real. The WHO has spoken.
But a breakthrough that only reaches the wealthy isn’t really a breakthrough. It’s a widening of an already deep divide. Obesity is more common among those with less. The drugs that treat it are accessible mainly to those with more. Until that changes, the gold rush will keep minting winners at the top while leaving the most vulnerable behind.
The drugs exist. The question is whether the political will to make them accessible does too.